Systemic Immune-Inflammatory Index, Tumor-Infiltrating Lymphocytes, and Clinical Outcomes in Esophageal Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy

<div>Multivariate survival analysis of OS (a) and PFS (b). OS, overall survival; PFS, progression-free survival; T, tumor; N, node; M, metastasis; cCR, clinical complete response; TIL, tumor-infiltrating lymphocytes; LMR, lymphocyte-to-monocyte ratio; HR, hazard ratio; CI, confidence interval.</div>

Journal of Immunology Research

fig2

Figure 2

Figure 2: Systemic Immune-Inflammatory Index, Tumor-Infiltrating Lymphocytes, and Clinical Outcomes in Esophageal Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy 

Figure 2 | Systemic Immune-Inflammatory Index, Tumor-Infiltrating Lymphocytes, and Clinical Outcomes in Esophageal Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy 